Adenovirus-based vaccines against avian-origin H5N1 influenza viruses

Microbes and Infection

Volumn 17, Issue 2, 2015, Pages 135-141

  He, Biao ^a   Zheng, Bo jian ^b   Wang, Qian ^a   Du, Lanying ^c   Jiang, Shibo ^a,c   Lu, Lu ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c NEW YORK BLOOD CENTER   (United States)

Author keywords

Adenovirus; H5N1; Mucosal; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; AVIAN INFLUENZA VACCINE; INFLUENZA VACCINE;

ARTICLE; DRUG ADMINISTRATION ROUTE; HUMAN; IMMUNE SYSTEM; INFLUENZA A; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; NONHUMAN; PRIORITY JOURNAL; VIRUS TRANSMISSION; ADENOVIRIDAE; ANIMAL; AVIAN INFLUENZA; BIRD; CHINA; IMMUNOLOGY; INFECTION CONTROL; INFLUENZA A VIRUS (H5N1); INFLUENZA, HUMAN; TRANSMISSION; VIROLOGY;

ADENOVIRIDAE; AVES; ORTHOMYXOVIRIDAE;

ADENOVIRIDAE; ANIMALS; BIRDS; CHINA; COMMUNICABLE DISEASE CONTROL; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 84921543906     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2014.11.003     Document Type: Article

References (70)

1. Wu Y., Wu Y., Tefsen B., Shi Y., Gao G.F. Bat-derived influenza-like viruses H17N10 and H18N11. Trends Microbiol 2014, 22:183-191.
2. Hoffmann E., Stech J., Leneva I., Krauss S., Scholtissek C., Chin P.S., et al. Characterization of the influenza A virus gene pool in avian species in southern China: was H6N1 a derivative or a precursor of H5N1?. J Virol 2000, 74:6309-6315.
3. Shortridge K.F., Zhou N.N., Guan Y., Gao P., Ito T., Kawaoka Y., et al. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology 1998, 252:331-342.
4. Zhao H., Zhou J., Jiang S., Zheng B.J. Receptor binding and transmission studies of H5N1 influenza virus in mammals. Emerg Microb Infect 2013, 2:e85. 10.1038/emi.2013.89.
5. Valkenburg S.A., Rutigliano J.A., Ellebedy A.H., Doherty P.C., Thomas P.G., Kedzierska K. Immunity to seasonal and pandemic influenza A viruses. Microbes Infect 2011, 13:489-501.
6. Le T.H., Nguyen N.T. Evolutionary dynamics of highly pathogenic avian influenza A/H5N1 HA clades and vaccine implementation in Vietnam. Clin Exp Vaccine Res 2014, 3:117-127.
7. Xu X., Subbarao, Cox N.J., Guo Y. Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology 1999, 261:15-19.
8. Peiris J.S., Yu W.C., Leung C.W., Cheung C.Y., Ng W.F., Nicholls J.M., et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004, 363:617-619.
9. Tran T.H., Nguyen T.L., Nguyen T.D., Luong T.S., Pham P.M., Nguyen v, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004, 350:1179-1188.
10. Liu J., Xiao H., Lei F., Zhu Q., Qin K., Zhang X.W., et al. Highly pathogenic H5N1 influenza virus infection in migratory birds. Science 2005, 309:1206.
11. Zhou J.Y., Shen H.G., Chen H.X., Tong G.Z., Liao M., Yang H.C., et al. Characterization of a highly pathogenic H5N1 influenza virus derived from bar-headed geese in China. J Gen Virol 2006, 87:1823-1833.
12. Ungchusak K., Auewarakul P., Dowell S.F., Kitphati R., Auwanit W., Puthavathana P., et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 2005, 352:333-340.
13. Kandun I.N., Wibisono H., Sedyaningsih E.R., Yusharmen, Hadisoedarsuno W., Purba W., et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med 2006, 355:2186-2194.
14. Wang H., Feng Z., Shu Y., Yu H., Zhou L., Zu R., et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet 2008, 371:1427-1434.
15. Herfst S., Schrauwen E.J., Linster M., Chutinimitkul S., de W.E., Munster V.J., et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 2012, 336:1534-1541.
16. Zhang Y., Zhang Q., Kong H., Jiang Y., Gao Y., Deng G., et al. H5N1 hybrid viruses bearing 2009/H1N1 virus genes transmit in guinea pigs by respiratory droplet. Science 2013, 340:1459-1463.
17. Imai M., Watanabe T., Hatta M., Das S.C., Ozawa M., Shinya K., et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 2012, 486:420-428.
18. Chen L.M., Blixt O., Stevens J., Lipatov A.S., Davis C.T., Collins B.E., et al. Invitro evolution of H5N1 avian influenza virus toward human-type receptor specificity. Virology 2012, 422:105-113.
19. Brady R.C., Treanor J.J., Atmar R.L., Keitel W.A., Edelman R., Chen W.H., et al. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 2009, 27:5091-5095.
20. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354:1343-1351.
21. Lu L., Liu Q., Jiang S. Biosecurity and biosafety in research on emerging pathogens. Emerg Microb Infect 2012, 1:e44.
22. Khurana S., Wu J., Verma N., Verma S., Raghunandan R., Manischewitz J., et al. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol 2011, 85:10945-10954.
23. Zheng N., B J., Lu L., Zhou Y., Jiang S., Du L. The advancement in the development of subunit influenza vaccines. Microbes Infect 2014 Dec, [Epub ahead of print].
24. Anderson R.D., Haskell R.E., Xia H., Roessler B.J., Davidson B.L. A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther 2000, 7:1034-1038.
25. Wang Q., Jia X.C., Finer M.H. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Ther 1995, 2:775-783.
26. Mitani K., Graham F.L., Caskey C.T., Kochanek S. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci U S A 1995, 92:3854-3858.
27. Fejer G., Freudenberg M., Greber U.F., Gyory I. Adenovirus-triggered innate signalling pathways. Eur J Microbiol Immunol (Bp) 2011, 1:279-288.
28. Zhu J., Huang X., Yang Y. Innate immune response to adenoviral vectors is mediated by both toll-like receptor-dependent and -independent pathways. J Virol 2007, 81:3170-3180.
29. Hoshino K., Sugiyama T., Matsumoto M., Tanaka T., Saito M., Hemmi H., et al. IkappaB kinase-alpha is critical for interferon-alpha production induced by toll-like receptors 7 and 9. Nature 2006, 440:949-953.
30. Lam E., Stein S., Falck-Pedersen E. Adenovirus detection by the cGAS/STING/TBK1 DNA sensing cascade. J Virol 2014, 88:974-981.
31. Fejer G., Drechsel L., Liese J., Schleicher U., Ruzsics Z., Imelli N., et al. Key role of splenic myeloid DCs in the IFN-alphabeta response to adenoviruses invivo. PLoS Pathog 2008, 4:e1000208.
32. Gao W., Soloff A.C., Lu X., Montecalvo A., Nguyen D.C., Matsuoka Y., et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 2006, 80:1959-1964.
33. Toro H., Tang D.C., Suarez D.L., Sylte M.J., Pfeiffer J., Van Kampen K.R. Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector. Vaccine 2007, 25:2886-2891.
34. Hoelscher M.A., Singh N., Garg S., Jayashankar L., Veguilla V., Pandey A., et al. A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. J Infect Dis 2008, 197:1185-1188.
35. Vemula S.V., Ahi Y.S., Swaim A.M., Katz J.M., Donis R., Sambhara S., et al. Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness. PLoS One 2013, 8:e62496.
36. Scallan C.D., Tingley D.W., Lindbloom J.D., Toomey J.S., Tucker S.N. An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol 2013, 20:85-94.
37. Lo C.Y., Wu Z., Misplon J.A., Price G.E., Pappas C., Kong W.P., et al. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine 2008, 26:2062-2072.
38. Gurwith M., Lock M., Taylor E.M., Ishioka G., Alexander J., Mayall T., et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 2013, 13:238-250.
39. Antrobus R.D., Coughlan L., Berthoud T.K., Dicks M.D., Hill A.V., Lambe T., et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens. Mol Ther 2014, 22:668-674.
40. Bangari D.S., Shukla S., Mittal S.K. Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochem Biophys Res Commun 2005, 327:960-966.
41. Singh N., Pandey A., Jayashankar L., Mittal S.K. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol Ther 2008, 16:965-971.
42. Pandey A., Singh N., Vemula S.V., Couetil L., Katz J.M., Donis R., et al. Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine. PLoS One 2012, 7:e33428.
43. Ehrhardt C., Seyer R., Hrincius E.R., Eierhoff T., Wolff T., Ludwig S. Interplay between influenza A virus and the innate immune signaling. Microbes Infect 2010, 12:81-87.
44. Ichinohe T., Kawaguchi A., Tamura S., Takahashi H., Sawa H., Ninomiya A., et al. Intranasal immunization with H5N1 vaccine plus poly I: poly C12U, a toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect 2007, 9:1333-1340.
45. Seibert C.W., Rahmat S., Krause J.C., Eggink D., Albrecht R.A., Goff P.H., et al. Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs. J Virol 2013, 87:7793-7804.
46. Song Y., Wang Y., Thakur R., Meidan V.M., Michniak B. Mucosal drug delivery: membranes, methodologies, and applications. Crit Rev Ther Drug Carr Syst 2004, 21:195-256.
47. Tutykhina I.L., Logunov D.Y., Shcherbinin D.N., Shmarov M.M., Tukhvatulin A.I., Naroditsky B.S., et al. Development of adenoviral vector-based mucosal vaccine against influenza. J Mol Med (Berl) 2011, 89:331-341.
48. Hoelscher M.A., Garg S., Bangari D.S., Belser J.A., Lu X., Stephenson I., et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006, 367:475-481.
49. Song K., Bolton D.L., Wei C.J., Wilson R.L., Camp J.V., Bao S., et al. Genetic immunization in the lung induces potent local and systemic immune responses. Proc Natl Acad Sci U S A 2010, 107:22213-22218.
50. Park K.S., Lee J., Ahn S.S., Byun Y.H., Seong B.L., Baek Y.H., et al. Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge. Virology 2009, 395:182-189.
51. Kim S.H., Kim J.Y., Choi Y., Nguyen H.H., Song M.K., Chang J. Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection. PLoS One 2013, 8:e75460.
52. Price G.E., Soboleski M.R., Lo C.Y., Misplon J.A., Quirion M.R., Houser K.V., et al. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One 2010, 5:e13162.
53. Du L., Zhou Y., Jiang S. Research and development of universal influenza vaccines. Microbes Infect 2010, 12:280-286.
54. Freidl G.S., Meijer A., de B.E., de N.M., Munoz O., Capua I., et al. Influenza at the animal-human interface: a review of the literature for virological evidence of human infection with swine or avian influenza viruses other than A(H5N1). Euro Surveill 2014, 19.
55. Du L., He Y., Wang Y., Zhang H., Ma S., Wong C.K., et al. Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: implication for developing SARS vaccines. Virology 2006, 353:6-16.
56. Du L., Zhao G., Lin Y., Chan C., He Y., Jiang S., et al. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine 2008, 26:1644-1651.
57. Sarukhan A., Camugli S., Gjata B., von B.H., Danos O., Jooss K. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J Virol 2001, 75:269-277.
58. Lu L., He B., Jiang S. The outbreak of avian influenza A (H7N9) in China: current status and future prospects. Biomed J 2013, 36:96-97.
59. Lu L., Liu Q., Du L., Jiang S. Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microbes Infect 2013, 15:625-629.
60. Liu Q., Lu L., Sun Z., Chen G.W., Wen Y., Jiang S. Genomic signature and protein sequence analysis of a novel influenza A (H7N9) virus that causes an outbreak in humans in China. Microbes Infect 2013, 15:432-439.
61. Zhu W., Shu Y. Genetic tuning of avian influenza A (H7N9) virus promotes viral fitness within different species. Microbes Infect 2014 Dec, [Epub ahead of print].
62. Jiang S., Lu L., Liu Q., Xu W., Du L. Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. Emerg Microb Infect 2012, 1:e13.
63. Rao S.S., Kong W.P., Wei C.J., Van H.N., Gorres J.P., Nason M., et al. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS One 2010, 5:e9812.
64. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007, 13:426-435.
65. Roy S., Kobinger G.P., Lin J., Figueredo J., Calcedo R., Kobasa D., et al. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine 2007, 25:6845-6851.
66. Hoelscher M.A., Jayashankar L., Garg S., Veguilla V., Lu X., Singh N., et al. New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. Clin Pharmacol Ther 2007, 82:665-671.
67. Patel A., Tikoo S., Kobinger G. A porcine adenovirus with low human seroprevalence is a promising alternative vaccine vector to human adenovirus 5 in an H5N1 virus disease model. PLoS One 2010, 5:e15301.
68. Price G.E., Soboleski M.R., Lo C.Y., Misplon J.A., Pappas C., Houser K.V., et al. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 2009, 27:6512-6521.
69. Alexander J., Ward S., Mendy J., Manayani D.J., Farness P., Avanzini J.B., et al. Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. PLoS One 2012, 7:e31177.
70. Holman D.H., Wang D., Raja N.U., Luo M., Moore K.M., Woraratanadharm J., et al. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses. Vaccine 2008, 26:2627-2639.